ライフサイエンスコーパス: placebo-controlled trial

1 dilatator sildenafil in a double-blinded and placebo-controlled trial.

2 s a single-centre, randomized, double-blind, placebo-controlled trial.

3 a pre-registered, randomised, double-blind, placebo-controlled trial.

4 icipated in this double-blinded, randomized, placebo-controlled trial.

5 were randomly assigned in a double-blinded, placebo-controlled trial.

6 a multicenter, randomized (1:1 allocation), placebo-controlled trial.

7 y.This study was a randomized, double-blind, placebo-controlled trial.

8 presentation in a prospective, double blind, placebo-controlled trial.

9 e causally linked, ideally in a double-blind placebo-controlled trial.

10 an international, randomised, double-blind, placebo-controlled trial.

11 h frequent episodes of IA in a double-blind, placebo-controlled trial.

12 : an international randomised, double-blind, placebo-controlled trial.

13 pain enrolled in a double-blind, randomized, placebo-controlled trial.

14 to 3 at 8-week intervals in a double blind, placebo-controlled trial.

15 efficacy of this treatment in a randomized, placebo-controlled trial.

16 three at 8-week intervals in a double blind, placebo-controlled trial.

17 each improved psychotic and mood symptoms in placebo-controlled trials.

18 ey were not designed as randomised, blinded, placebo-controlled trials.

19 through antiretroviral therapy interruption placebo-controlled trials.

20 extracted design settings from 13 completed placebo-controlled trials.

21 its and harms of active interventions within placebo-controlled trials.

22 In a randomised double-blind, placebo controlled trial, 22 early onset PD patients, we

23 : In this phase I, randomized, double-blind, placebo-controlled trial, 48 healthy volunteers, aged 18

24 In a randomized, placebo-controlled trial, 606 newborns with at least one

25 In a multicenter, double-blind, randomized, placebo-controlled trial, 62 patients were allocated to

26 In a 24-wk randomized, double-blinded, placebo-controlled trial, 622 participants were assigned

27 17 randomised placebo-controlled trials (6729 participants) reported a

28 tive, multicenter, randomized, double-blind, placebo-controlled trial, 96 HT recipients were randomiz

29 We conducted a randomized, double-blind, placebo-controlled trial across the United States and pa

30 is international, multicentre, double-blind, placebo-controlled trial, adult patients (>/=18 years) w

31 this multicentre, randomised, double-blind, placebo-controlled trial, adults (>/=18 years) with S au

32 In this randomized, placebo-controlled trial, adults with newly diagnosed or

33 In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a

34 genicity and viral shedding in a randomized, placebo-controlled trial among Bangladeshi children.

35 tland Coronary Prevention Study) randomized, placebo-controlled trial, and observational posttrial lo

36 This phase 1/2, placebo-controlled trial assessed effects of ziltivekima

37 This exploratory double-blind randomized placebo-controlled trial assessed the acute (1 hour, 2 h

38 This randomized, double-blind, placebo-controlled trial assessed the effects of tenapan

39 women in VOICE, randomized, double-blinded, placebo-controlled trial assessing daily use of oral and

40 rm, parallel group, double-blind, randomised placebo-controlled trial at 13 clinical neuroscience cen

41 (SHIP) Study was a randomised, double-blind, placebo-controlled trial at 25 cystic fibrosis centres i

42 did a double-blind, multicentre, randomised placebo-controlled trial at 33 hospital maternity units

43 was a multicentre, randomised, double-blind, placebo-controlled trial at 371 sites in 24 countries.

44 REWIND is a randomised, double-blind placebo-controlled trial at 371 sites in 24 countries.

45 In this randomised, double-blind, placebo-controlled trial at 590 sites in 42 countries, w

46 We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries.

47 Double-blinded, placebo-controlled trial at 9 academic medical centers i

48 centre, phase 2/3, randomised, double-blind, placebo-controlled trial at 92 sites in the USA.

49 e, randomised, double-blind, parallel-group, placebo-controlled trial at Glenfield Hospital (Leiceste

50 We did a randomised, double-blind, placebo-controlled trial at the Thai Red Cross AIDS Rese

51 We did a large, phase 2, double-blind, placebo-controlled trial at three sites in the Dominican

52 We did a randomised, double-blind, placebo-controlled, trial at 32 health centres in Bangla

53 y cohort, we did a double-blind, randomised, placebo-controlled trial based in Doneguebougou and surr

54 recruited for this double-blind, randomized, placebo-controlled trial between 2016 and 2019.

55 In double-blind, placebo-controlled trials, budesonide-formoterol used on

56 med our study as a randomized, double-blind, placebo-controlled trial by training other subjects in a

57 In this double-blind, multicenter, placebo-controlled trial, cardiotoxicity and treatment i

58 III, multicenter, randomized, double-blind, placebo-controlled trial (clinical.govNCT02560948).

59 A 24-week, double-blinded, randomised, placebo-controlled trial (ClinicalTrials.gov: NCT0067323

60 ODS AND TIME was a randomized, double-blind, placebo-controlled trial comparing 150 million bone marr

61 SEY OUTCOMES was a randomized, double-blind, placebo-controlled trial comparing alirocumab or placebo

62 We conducted a double-blinded, randomized, placebo-controlled trial comparing daily TMP-SMX plus mo

63 re included in the randomized, double-blind, placebo-controlled trial, comprising 3 years of treatmen

64 participants in a randomized, double-blind, placebo-controlled trial conducted at 11 clinical center

65 ICIPANTS: Phase 3, randomized, double-blind, placebo-controlled trial conducted at 31 sites in 5 coun

66 this prospective, double-blind, randomized, placebo-controlled trial conducted at two tertiary care

67 In a double-blind, placebo-controlled trial conducted from 1998 through 200

68 Randomized, double-blind, placebo-controlled trial conducted in 13 French cardiac

69 uction Trial was a randomized, double-blind, placebo-controlled trial conducted in 3 centers across t

70 was a multicenter, double-blind, randomized placebo-controlled trial conducted in Auckland and Brisb

71 A randomized, double-blind, multisite placebo-controlled trial conducted in human subjects dem

72 h Malaria) was a randomized, double-blinded, placebo-controlled trial conducted in malaria-endemic Ug

73 ND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 c

74 R criteria were enrolled in this randomized, placebo-controlled trial consisting of an initial 12- to

75 In this double-blind, placebo-controlled trial (DELIGHT), we enrolled patients

76 ng a crossover, randomized, double-blind and placebo-controlled trial design, 16 healthy female adult

77 the AIMS trial, a randomised, double-blind, placebo-controlled trial designed to evaluate the effect

78 a randomised, double-blind, parallel-group, placebo-controlled trial done at 90 academic and communi

79 t 1 consisted of a randomised, double-blind, placebo-controlled trial done over 18 months.

80 SEY OUTCOMES was a randomised, double-blind, placebo-controlled trial, done at 1315 sites in 57 count

81 S) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 count

82 /- SD) completed this randomized, crossover, placebo-controlled trial during two laboratory visits.

83 A randomized, double-blind, placebo-controlled trial (Effects of Psychotropic Drugs

84 pendent fashion in a randomized double-blind placebo-controlled trial (Effects of Psychotropic Medica

85 A phase 1-2 randomized double-blind placebo-controlled trial enrolled 252 participants (210

86 METHODS AND Randomized, double-blinded, placebo-controlled trial enrolled 31 patients with recur

87 Randomized, double-blinded, placebo-controlled trial enrolled 31 patients with recur

88 In a double-blind, placebo-controlled trial enrolling females with dry skin

89 is highlights the need for more high-quality placebo-controlled trials, equipoise may no longer be gu

90 A phase 2, double-blind, placebo-controlled trial evaluated apremilast efficacy,

91 Methods In the MAP.3 randomized, placebo-controlled trial evaluating exemestane, particip

92 ents), who were previously participants in a placebo-controlled trial evaluating the 2-year efficacy

93 In this phase 3, randomised, double-blind, placebo-controlled trial (EXPLORER-HCM) in 68 clinical c

94 was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruit

95 Placebo-controlled trials for cognitive impairment assoc

96 Randomized, placebo-controlled trial from July 2014 to May 2016.

97 We performed a multicenter, double-blind, placebo-controlled trial, from March 2016 through April

98 We conducted a 24-wk randomized placebo-controlled trial in 126 overweight, non-insulin

99 nducted a phase 2, randomized, double-blind, placebo-controlled trial in 27 centers across North Amer

100 MTN-027, a single-blind, randomized, placebo-controlled trial in 48 women, evaluated VRs cont

101 We undertook this randomised, double-blind, placebo-controlled trial in a general adult intensive ca

102 As part of a double-blind, randomized, placebo-controlled trial in Mozambique using monthly che

103 We conducted a randomized, placebo-controlled trial in Niger to evaluate the effica

104 In a double-blind, placebo-controlled trial in Niger, we randomly assigned

105 ducted a multicenter, two-group, randomized, placebo-controlled trial in nine hospitals in Kenya and

106 udy consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chroni

107 was a phase 3, international, double-blind, placebo-controlled trial in patients with symptomatic PA

108 hase 2 double-blind, multicentre, randomised placebo-controlled trial in previously untreated adult p

109 ion and immune activation in a double-blind, placebo-controlled trial in PWH at moderate CVD risk was

110 try, parallel arm, double-blind, randomised, placebo-controlled trial in South Africa, Zimbabwe, and

111 ave GI problems, and warrant a double-blind, placebo-controlled trial in the future.

112 We conducted a randomized, double-blind, placebo-controlled trial in treatment-naive T2DM individ

113 This was a randomized, double-blind, placebo-controlled trial in which patients with severe a

114 We report two double-blind, randomised, placebo-controlled trials in adults with chronic non-can

115 The authors present a meta-analysis of all placebo-controlled trials in patients with acute exacerb

116 ve largely failed to demonstrate efficacy in placebo-controlled trials in schizophrenia.

117 ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in southern Africa with harmon

118 ed about the ethics of conducting randomized placebo-controlled trials in the midst of a rapidly spre

119 a challenge to design rigorous, randomized, placebo-controlled trials, in part owing to problems of

120 This randomized, placebo-controlled trial included 4- to 6-month-old infa

121 THOD: This 6-week, randomized, double-blind, placebo-controlled trial included patients with schizoph

122 This randomized, double-blind, placebo-controlled trial included patients with type 2 d

123 SHIFT was a randomized placebo-controlled trial investigating the effect of iva

124 was a multicenter, randomized, double-blind, placebo-controlled trial involving 17 hospitals in Austr

125 Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving 201 patients with sta

126 We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with

127 We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with at

128 tigator-initiated, randomized, double-blind, placebo-controlled trial involving 308 patients hospital

129 ted a multicenter, double-blind, randomized, placebo-controlled trial involving adult patients (>18 y

130 In this phase 3 randomized, placebo-controlled trial involving participants with sic

131 n an event-driven, randomized, double-blind, placebo-controlled trial involving patients at high card

132 ted a multicenter, randomized, double-blind, placebo-controlled trial involving patients in whom peri

133 FOURIER was a randomized, double-blind, placebo-controlled trial involving patients with atheros

134 We performed a randomized, double-blind, placebo-controlled trial involving patients with confirm

135 med a multicenter, randomized, double-blind, placebo-controlled trial involving patients with establi

136 A randomized, placebo-controlled trial is needed to determine if oral

137 week, prospective, double-blind, randomized, placebo-controlled trial (methylphenidate versus placebo

138 In this double-blind, placebo-controlled trial, nondiabetic HFrEF patients (n

139 re search in MEDLNE and included randomized, placebo controlled trials of RAAS inhibitors in chronic

140 y, nested within a randomized, double-blind, placebo-controlled trial of 141 adults with uncomplicate

141 The protocol for a phase 2 placebo-controlled trial of 2 Ebola vaccines was amended

142 We performed a single-center, double-blind, placebo-controlled trial of 2 separate cohorts (March 20

143 We performed a randomized, double-blinded, placebo-controlled trial of 5,110 adults, aged 50-84 yea

144 We performed a randomized, double-blinded, placebo-controlled trial of 5110 adults aged 50-84 years

145 nducted a randomized, double-blind, Phase II placebo-controlled trial of a monoclonal antibody that t

146 icrobicide Trials Network-020, a randomized, placebo-controlled trial of a monthly, dapivirine vagina

147 We conducted a randomized, double-blinded, placebo-controlled trial of a replication-defective HSV2

148 a double-blind, randomized, parallel-group, placebo-controlled trial of a single ketamine infusion (

149 n ongoing phase 2, randomised, double-blind, placebo-controlled trial of a TDV is being done at three

150 CSF from patients enrolled into a randomized placebo-controlled trial of adjunctive aspirin treatment

151 conducted an 8-week randomized double-blind placebo-controlled trial of adjunctive testosterone crea

152 This randomized double-blind placebo-controlled trial of adult outpatients with anore

153 We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline (1 mg per kilo

154 nine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a stati

155 ere we report on a randomized, double-blind, placebo-controlled trial of an oral synbiotic preparatio

156 We performed a randomized, double-blind, placebo-controlled trial of anastrozole in patients with

157 We conducted a double blind, randomized, placebo-controlled trial of azithromycin (20 mg/kg/day)

158 We did a randomised, double-blind, placebo-controlled trial of canakinumab in 10 061 patien

159 ects enrolled in a randomized, double-blind, placebo-controlled trial of Cat-PAD, we employed Fel d 1

160 lled in a randomized, 3-month double-masked, placebo-controlled trial of daily 2 g DHA or placebo cap

161 ata from women in the Partners PrEP Study, a placebo-controlled trial of daily oral PrEP (either teno

162 is of the Partners PrEP Study, a randomized, placebo-controlled trial of daily oral TDF, alone or wit

163 ex-CSDH trial is a randomised, double-blind, placebo-controlled trial of dexamethasone for patients w

164 MDD patients enrolled in a large, randomized placebo-controlled trial of duloxetine collected before

165 s With EPA Intervention Trial), a randomized placebo-controlled trial of EPA-only in high-risk patien

166 recently published double-blind, randomized, placebo-controlled trial of escitalopram or escitalopram

167 In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin t

168 lled in an 8-week, randomized, double-blind, placebo-controlled trial of guanfacine plus cognitive re

169 (ViDA) Study was a randomised, double-blind, placebo-controlled trial of healthy volunteers aged 50-8

170 s a randomised, multicountry, double-masked, placebo-controlled trial of low-dose aspirin (81 mg dail

171 t baseline and multiple time points during a placebo-controlled trial of OIT for milk allergy in whic

172 evelopment was done with data from a phase 2 placebo-controlled trial of ozanimod in patients with mo

173 rvention After Stroke trial, a double-blind, placebo-controlled trial of pioglitazone for secondary p

174 is, we conducted a randomized, double-blind, placebo-controlled trial of pioglitazone therapy on GIP-

175 formed a 12-month, randomized, double-blind, placebo-controlled trial of pomegranate juice in middle-

176 e Parents (ECAP) were tested in a randomized placebo-controlled trial of pre-emptive high-dose flutic

177 We conducted a randomized, double-blind, placebo-controlled trial of pregabalin in patients with

178 Randomized, double-blind, placebo-controlled trial of single dose reltecimod (0.5

179 scans from 160 participants in a randomized placebo-controlled trial of stem cell therapy for patien

180 In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarat

181 usly conducted coffee trials in a randomized placebo-controlled trial of the effect of coffee consump

182 were enrolled in a randomized, double-blind, placebo-controlled trial of the humanized anti-IL-5 anti

183 and Safety) trial: a 48-week, double-blind, placebo-controlled trial of thrice-weekly 500 mg oral az

184 (ViDA) study was a randomized, double-blind, placebo-controlled trial of vitamin D supplementation in

185 This was a randomised, double-blind, placebo-controlled trial of vitamin D(3) supplementation

186 ed favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less

187 on 54) (ticagrelor) were blinded, randomized placebo-controlled trials of antiplatelet therapy for th

188 -defined serious adverse events occurring in placebo-controlled trials of antipsychotics.

189 rom two phase III, randomized, double-blind, placebo-controlled trials of IFN-gamma-1b in idiopathic

190 2018, to identify double blind, randomised, placebo-controlled trials of macrolide antibiotics in ad

191 5/23 received leronlimab after blinded placebo-controlled trials of remdesivir, sarilumab, seli

192 Jan 31, 2016, for randomised, double-blind, placebo-controlled trials of second-generation antidepre

193 ted cirrhosis (F4) enrolled in two phase 2b, placebo-controlled trials of simtuzumab.

194 We completed two double-blind, placebo-controlled trials of SNRI antidepressant medicat

195 ted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adul

196 al; however, clinical studies and randomized placebo-controlled trials of women with psychiatric diso

197 sitivity analyses that included 4 additional placebo-controlled trials, overall and subgroup findings

198 ated, multicenter, randomized, double-blind, placebo-controlled trial, patients who had been hospital

199 In this randomised, double-blind, placebo-controlled trial, patients with a diagnosis of i

200 Patients and Methods In this double-blinded, placebo-controlled trial, patients with HER2-positive ea

201 his single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkins

202 In this randomised, placebo-controlled trial, pregnant women in Bangalore, I

203 diovascular Outcomes Trial), a double-blind, placebo-controlled trial, randomly assigned patients wit

204 vention Trial), a multicenter, double-blind, placebo-controlled trial, randomly assigned statin-treat

205 nance imaging to a randomized, double-blind, placebo-controlled trial (RCT) of antidepressant medicat

206 This randomized, double-blind, placebo-controlled trial recruited patients aged 18 to 7

207 d even higher protection against HIV than in placebo-controlled trials, refuting concerns that effect

208 orical analysis both reaffirms that rigorous placebo-controlled trials remain indispensable tools in

209 l Register of Controlled Trials for eligible placebo-controlled trials reporting major adverse cardio

210 ERVE-AMI (Phase 2, randomized, double-blind, placebo-controlled trial) represents the largest study o

211 The largest placebo-controlled trial showed that standard dose of ep

212 Phase 3, double-blind, randomised, placebo-controlled trial (SP0982; NCT02408523) in patien

213 found in all four much smaller, randomized, placebo-controlled trials specifically designed to evalu

214 , it is no surprise that numerous randomized placebo-controlled trials studying acute pain following

215 the treatment of gambling disorder, although placebo-controlled trials suggest that some medications,

216 nd laboratory studies, as well as randomized placebo-controlled trials, suggests supplementation with

217 In placebo-controlled trials, tamoxifen (risk ratio [RR], 0

218 lth Study II was a randomized, double-blind, placebo-controlled trial testing multivitamin use (multi

219 We performed a randomized, double-blind, placebo-controlled trial testing the effects of inhaled

220 ducted a randomized, adaptive, double-blind, placebo-controlled trial that enrolled patients at nine

221 s a single-center, double-blind, randomized, placebo-controlled trial that included 100 community-dwe

222 was a multicenter, double-blind, randomized, placebo-controlled trial that randomly assigned patients

223 essment Study is a randomized, double-blind, placebo-controlled trial that recruited participants mos

224 In this randomized, placebo-controlled trial (the Bortezomib in Late Antibod

225 In a randomized, double-blind, placebo-controlled trial (the Dietary Intervention, Stem

226 ned a multicenter, randomized, double-blind, placebo-controlled trial (the SUGAR-DM-HF trial [Studies

227 In this randomized, placebo-controlled trial, the addition of ticagrelor to

228 e did an 18-month, randomised, double-blind, placebo-controlled trial (TIRCON2012V1), followed by a p

229 We did a phase 1, single-blind, randomised, placebo-controlled trial to assess safety, pharmacokinet

230 We performed a randomized, placebo-controlled trial to assess the effectiveness and

231 We conducted a randomized, double-blind, placebo-controlled trial to assess whether intravenous N

232 nducted a phase 3, randomized, double-blind, placebo-controlled trial to confirm the efficacy and saf

233 We conducted a randomized double-blinded placebo-controlled trial to determine the effect of uste

234 ed a multicenter, double-masked, randomized, placebo-controlled trial to determine the efficacy and s

235 We performed a randomized placebo-controlled trial to determine the long-term effi

236 multicenter, double-blind, block-randomized, placebo-controlled trial to determine whether folic acid

237 performed the first randomized double-blind placebo-controlled trial to evaluate efficacy of intrave

238 ted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate progesterone, as co

239 nducted a 24-week, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and sa

240 rom 1092 patients enrolled in a double-blind placebo-controlled trial to evaluate the efficacy of tre

241 We undertook a multisite, randomized, placebo-controlled trial to evaluate whether naloxone is

242 ticenter, phase 3, randomized, double-blind, placebo-controlled trial to investigate the efficacy and

243 We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and

244 s conducted a 6-week randomized double-blind placebo-controlled trial to investigate the efficacy of

245 We conducted a double-blind, placebo-controlled trial to investigate whether levothyr

246 ps, we conducted a double-blind, randomized, placebo-controlled trial to investigate whether vitamin

247 e-blind, randomized, investigator-initiated, placebo-controlled trial to test the efficacy of 12 week

248 REMOVAL was a double-blind, placebo-controlled trial undertaken at 23 hospital diabe

249 1313/I1314L was evaluated in a double-blind, placebo-controlled trial (vaccine-placebo ratio, 2:1) at

250 This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers acr

251 Methods: A randomized, double-blind, placebo-controlled trial was conducted at three centers.

252 This randomized double-blind, placebo-controlled trial was conducted between October 2

253 rch 2014 through March 2017, a double-blind, placebo-controlled trial was conducted in 260 participan

254 d, double-dummy, parallel group, randomized, placebo-controlled trial was conducted in Ethiopia, Peru

255 A factorial, randomized, double-blind, placebo-controlled trial was conducted in infertility cl

256 d, double-blind, parallel-group, multicentre placebo-controlled trial was done at 22 hospitals in the

257 This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 cou

258 n-human, double-blind, parallel, randomised, placebo-controlled trial was done at Hammersmith Hospita

259 A randomised, placebo-controlled trial was done at six academic hospit

260 This multicenter, randomized, double-blind, placebo-controlled trial was performed at 2 university m

261 This randomised, double-blind, placebo-controlled trial was planned for 45 hospitals in

262 The purpose of this double-blind randomized placebo-controlled trial was to investigate the effect o

263 A randomized, double-blind, placebo-controlled trial was used.

264 ejection fraction <50% from 10 double-blind, placebo-controlled trials was performed.

265 In part 1 of this phase 2, randomized, placebo-controlled trial we sequentially enrolled 1.5-45

266 n a 3-year follow-up double-blind randomized placebo-controlled trial, we aimed to investigate the ef

267 this multicenter, double-blind, randomized, placebo-controlled trial, we assessed the efficacy and s

268 In this phase 3, randomized, double-blind, placebo-controlled trial, we assigned 5050 patients with

269 In this phase 2, randomized, double-blind, placebo-controlled trial, we compared subcutaneous tezep

270 ticenter, phase 3, double-blind, randomized, placebo-controlled trial, we compared the efficacy and s

271 In the GRAVITAS randomised double-blind, placebo-controlled trial, we enrolled adults who had und

272 For this double-blind, randomised, placebo-controlled trial, we enrolled self-referred or p

273 In this phase 4, randomised, placebo-controlled trial, we enrolled two consecutive se

274 In this double-blind randomised placebo-controlled trial, we enrolled undiagnosed patien

275 In a double-blind, randomized, placebo-controlled trial, we examined the acute and dela

276 In a placebo-controlled trial, we found that the probiotic BL

277 In this randomized, double-blind, placebo-controlled trial, we investigated the effect of

278 In this randomised, double-blind, placebo-controlled trial, we randomly allocated 172 57 (

279 ntre phase 1b, first-in-human, single-blind, placebo-controlled trial, we randomly assigned (1:1) hea

280 In this double-blind, placebo-controlled trial, we randomly assigned 120 child

281 In this double-blind, placebo-controlled trial, we randomly assigned 1509 men,

282 In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1776 wome

283 In this double-blind, randomized, placebo-controlled trial, we randomly assigned men and w

284 In a phase 2, randomized, double-blind, placebo-controlled trial, we randomly assigned, in a 1:1

285 In this double-blind, randomised, placebo-controlled trial, we recruited HIV-positive adul

286 ble-blind, multicentre, phase 2b, randomised placebo-controlled trial, we recruited patients who had

287 s: In a multicenter, randomized double-blind placebo-controlled trial, we studied retreatment with or

288 n a preregistered, randomized, double-blind, placebo-controlled trial, we tested the effect of a sing

289 is randomised, parallel-group, double-blind, placebo-controlled trial were recruited via newspaper ad

290 with TD who completed the 12 week, phase 3, placebo-controlled trials were eligible to enter this op

291 rse event (AE) rates derive from randomized, placebo-controlled trials, where both causality and magn

292 o determine, in a multicenter double-blinded placebo-controlled trial, whether maximal hepatic arteri

293 This study was a randomized placebo-controlled trial with 155 participants aged 60-8

294 This was a randomized, double-blind, placebo-controlled trial with 634 subjects (12-65 years)

295 med a multicenter, randomized, double-blind, placebo-controlled trial with Alt a 1 administered subcu

296 We thus performed a randomized placebo-controlled trial with atorvastatin 40 mg/day for

297 hence conducted a randomized, double-blind, placebo-controlled trial with newly diagnosed T2D patien

298 We conducted a randomized, placebo-controlled trial, with a two-by-two factorial de

299 We conducted a nationwide, randomized, placebo-controlled trial, with a two-by-two factorial de

300 quantified by comparing simulated randomised placebo-controlled trials within the out-of-sample LABS-